Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibroblast Activating Protein (FAP) PET/CT in Adults With Fibrotic Conditions
NCT06413355Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [18F]-FAPI-74 in fibrosis, sponsored by Abramson Cancer Center. Primary endpoints: Overall FAPI-74 PET/CT Image Analysis at 3 years, Head and Neck Cancer FAPI-74 PET/CT Image Analysis at 3 years and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
[18F]-FAPI-74
03
Conditions
fibrosis
Beyond the preview
Go deeper on NCT06413355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413355.